182 related articles for article (PubMed ID: 33837178)
1. WBP2 negatively regulates the Hippo pathway by competitively binding to WWC3 with LATS1 to promote non-small cell lung cancer progression.
Han Q; Rong X; Lin X; Zhang X; Fan C; Zhao H; Wang E
Cell Death Dis; 2021 Apr; 12(4):384. PubMed ID: 33837178
[TBL] [Abstract][Full Text] [Related]
2. WWC3 regulates the Wnt and Hippo pathways via Dishevelled proteins and large tumour suppressor 1, to suppress lung cancer invasion and metastasis.
Han Q; Lin X; Zhang X; Jiang G; Zhang Y; Miao Y; Rong X; Zheng X; Han Y; Han X; Wu J; Kremerskothen J; Wang E
J Pathol; 2017 Aug; 242(4):435-447. PubMed ID: 28543074
[TBL] [Abstract][Full Text] [Related]
3. WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ.
Chan SW; Lim CJ; Huang C; Chong YF; Gunaratne HJ; Hogue KA; Blackstock WP; Harvey KF; Hong W
Oncogene; 2011 Feb; 30(5):600-10. PubMed ID: 20972459
[TBL] [Abstract][Full Text] [Related]
4. WWC3 inhibits intimal proliferation following vascular injury via the Hippo signaling pathway.
Chen B; Liu G
Mol Med Rep; 2018 Apr; 17(4):5175-5183. PubMed ID: 29393412
[TBL] [Abstract][Full Text] [Related]
5. FRMPD1 activates the Hippo pathway via interaction with WWC3 to suppress the proliferation and invasiveness of lung cancer cells.
Rong X; Han Q; Lin X; Kremerskothen J; Wang E
Cancer Manag Res; 2019; 11():3395-3410. PubMed ID: 31114375
[No Abstract] [Full Text] [Related]
6. WBP2 promotes gastric cancer cell migration via novel targeting of LATS2 kinase in the Hippo tumor suppressor pathway.
Hum M; Tan HJ; Yang Y; Srivastava S; Teh M; Lim YP
FASEB J; 2021 Feb; 35(2):e21290. PubMed ID: 33475198
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal Regulation of Hippo and WBP2 Signalling-Implications in Cancer Therapy.
Lim YX; Lin H; Seah SH; Lim YP
Cells; 2021 Nov; 10(11):. PubMed ID: 34831354
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
9. Hippo/MST blocks breast cancer by downregulating WBP2 oncogene expression via miRNA processor Dicer.
Lim SK; Tabatabaeian H; Lu SY; Kang SA; Sundaram GM; Sampath P; Chan SW; Hong WJ; Lim YP
Cell Death Dis; 2020 Aug; 11(8):669. PubMed ID: 32820148
[TBL] [Abstract][Full Text] [Related]
10. WW domain-binding protein 2: an adaptor protein closely linked to the development of breast cancer.
Chen S; Wang H; Huang YF; Li ML; Cheng JH; Hu P; Lu CH; Zhang Y; Liu N; Tzeng CM; Zhang ZM
Mol Cancer; 2017 Jul; 16(1):128. PubMed ID: 28724435
[TBL] [Abstract][Full Text] [Related]
11. Wnt Signaling Promotes Breast Cancer by Blocking ITCH-Mediated Degradation of YAP/TAZ Transcriptional Coactivator WBP2.
Lim SK; Lu SY; Kang SA; Tan HJ; Li Z; Adrian Wee ZN; Guan JS; Reddy Chichili VP; Sivaraman J; Putti T; Thike AA; Tan PH; Sudol M; Virshup DM; Chan SW; Hong W; Lim YP
Cancer Res; 2016 Nov; 76(21):6278-6289. PubMed ID: 27578003
[TBL] [Abstract][Full Text] [Related]
12. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
13. WWC3 inhibits epithelial-mesenchymal transition of lung cancer by activating Hippo-YAP signaling.
Han Q; Kremerskothen J; Lin X; Zhang X; Rong X; Zhang D; Wang E
Onco Targets Ther; 2018; 11():2581-2591. PubMed ID: 29780251
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
15. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
[TBL] [Abstract][Full Text] [Related]
16. Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1.
Si Y; Ji X; Cao X; Dai X; Xu L; Zhao H; Guo X; Yan H; Zhang H; Zhu C; Zhou Q; Tang M; Xia Z; Li L; Cong YS; Ye S; Liang T; Feng XH; Zhao B
Cancer Res; 2017 Sep; 77(18):4868-4880. PubMed ID: 28754671
[TBL] [Abstract][Full Text] [Related]
17. TNFAIP8 regulates Hippo pathway through interacting with LATS1 to promote cell proliferation and invasion in lung cancer.
Han Y; Tang Z; Zhao Y; Li Q; Wang E
Mol Carcinog; 2018 Feb; 57(2):159-166. PubMed ID: 28926138
[TBL] [Abstract][Full Text] [Related]
18. Molecular chaperone Hsp27 regulates the Hippo tumor suppressor pathway in cancer.
Vahid S; Thaper D; Gibson KF; Bishop JL; Zoubeidi A
Sci Rep; 2016 Aug; 6():31842. PubMed ID: 27555231
[TBL] [Abstract][Full Text] [Related]
19. Biophysical studies and modelling indicate the binding preference of TAZ WW domain for LATS1 PPxY motif.
Verma A; Lin F; Tan YC; Hidayat MN; Jobichen C; Fan H; Sivaraman J
Biochem Biophys Res Commun; 2018 Jul; 502(3):307-312. PubMed ID: 29787761
[TBL] [Abstract][Full Text] [Related]
20. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]